Your browser doesn't support javascript.
loading
Multi-vendor evaluation of artificial intelligence as an independent reader for double reading in breast cancer screening on 275,900 mammograms.
Sharma, Nisha; Ng, Annie Y; James, Jonathan J; Khara, Galvin; Ambrózay, Éva; Austin, Christopher C; Forrai, Gábor; Fox, Georgia; Glocker, Ben; Heindl, Andreas; Karpati, Edit; Rijken, Tobias M; Venkataraman, Vignesh; Yearsley, Joseph E; Kecskemethy, Peter D.
Afiliação
  • Sharma N; The Leeds Teaching Hospital NHS Trust, Leeds, UK.
  • Ng AY; Kheiron Medical Technologies, London, UK. annie@kheironmed.com.
  • James JJ; Nottingham Breast Institute, City Hospital, Nottingham University Hospitals NHS Trust, Nottingham, UK.
  • Khara G; Kheiron Medical Technologies, London, UK.
  • Ambrózay É; MaMMa Egészségügyi Zrt, Budapest, Hungary.
  • Austin CC; Kheiron Medical Technologies, London, UK.
  • Forrai G; Duna Medical Center, Budapest, Hungary.
  • Fox G; GÉ-RAD Kft, Budapest, Hungary.
  • Glocker B; Kheiron Medical Technologies, London, UK.
  • Heindl A; Kheiron Medical Technologies, London, UK.
  • Karpati E; Department of Computing, Imperial College London, London, UK.
  • Rijken TM; Kheiron Medical Technologies, London, UK.
  • Venkataraman V; Kheiron Medical Technologies, London, UK.
  • Yearsley JE; Medicover, Budapest, Hungary.
  • Kecskemethy PD; Kheiron Medical Technologies, London, UK.
BMC Cancer ; 23(1): 460, 2023 May 19.
Article em En | MEDLINE | ID: mdl-37208717
ABSTRACT

BACKGROUND:

Double reading (DR) in screening mammography increases cancer detection and lowers recall rates, but has sustainability challenges due to workforce shortages. Artificial intelligence (AI) as an independent reader (IR) in DR may provide a cost-effective solution with the potential to improve screening performance. Evidence for AI to generalise across different patient populations, screening programmes and equipment vendors, however, is still lacking.

METHODS:

This retrospective study simulated DR with AI as an IR, using data representative of real-world deployments (275,900 cases, 177,882 participants) from four mammography equipment vendors, seven screening sites, and two countries. Non-inferiority and superiority were assessed for relevant screening metrics.

RESULTS:

DR with AI, compared with human DR, showed at least non-inferior recall rate, cancer detection rate, sensitivity, specificity and positive predictive value (PPV) for each mammography vendor and site, and superior recall rate, specificity, and PPV for some. The simulation indicates that using AI would have increased arbitration rate (3.3% to 12.3%), but could have reduced human workload by 30.0% to 44.8%.

CONCLUSIONS:

AI has potential as an IR in the DR workflow across different screening programmes, mammography equipment and geographies, substantially reducing human reader workload while maintaining or improving standard of care. TRIAL REGISTRATION ISRCTN18056078 (20/03/2019; retrospectively registered).
Assuntos
Palavras-chave

Texto completo: 1 Base de dados: MEDLINE Assunto principal: Neoplasias da Mama Tipo de estudo: Diagnostic_studies / Observational_studies / Risk_factors_studies / Screening_studies Limite: Female / Humans Idioma: En Ano de publicação: 2023 Tipo de documento: Article

Texto completo: 1 Base de dados: MEDLINE Assunto principal: Neoplasias da Mama Tipo de estudo: Diagnostic_studies / Observational_studies / Risk_factors_studies / Screening_studies Limite: Female / Humans Idioma: En Ano de publicação: 2023 Tipo de documento: Article